Teva bags HY debut success giving buyers rare premium
Investors this week showered orders on to the first bond issue from Teva Pharmaceuticals since a recent downgrade to high yield ratings. The hook? A 50bp-100bp premium over its old bonds in the secondary market.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: